DRL had stated on Wednesday that the BASF pharma transaction was subject to customary closing conditions and expected to be completed in the first quarter of the current financial year. The company announced that it would acquire Dowpharma Small Molecules a month ago. The financial details of both the transactions were not disclosed.
Besides the two deals, DRL had acquired Jet Generici Srl, a company engaged in the sale of generic finished dosages in Italy, last month. The deal has been completed through Dr Reddy's Italian subsidiary, Reddy Pharma Italia SpA, which has been engaged in building a pipeline of registrations since its incorporation.
